肺腺癌病理分级预测相关生物标志物研究进展——肿瘤病理分级预测标志物探索  

Research Progress of Biomarkers Related to Pathological Grading Prediction in Lung Adenocarcinoma—Exploration of Biomarkers for Lung Adenocarcinoma Grading Prediction

作　　者：黎杨 江德鹏[1] 

机构地区：[1]重庆医科大学附属第二医院呼吸与危重症医学科,重庆

出　　处：《临床医学进展》2025年第2期768-774,共7页Advances in Clinical Medicine

摘　　要：肺腺癌(LUAD)是非小细胞肺癌(NSCLC)的主要类型,其病理分级对于评估肿瘤侵袭性和预后至关重要。不同病理级别的LUAD在基因表达、TP53基因突变、转录因子FOSB、循环肿瘤细胞(CTC)以及外周血炎症因子等生物标志物表达上存在显著差异,可预测病理分级。因此,确定可靠的病理分级预测的生物标志物对治疗方案的选择至关重要。本文围绕LUAD病理分级预测相关的生物标志物进行综述,以期制定个体化治疗方案、改善预后。Lung adenocarcinoma (LUAD) is the predominant type of non-small cell lung cancer (NSCLC), and its pathological grading is crucial for assessing tumor aggressiveness and prognosis. LUADs of different pathological grades exhibit significant differences in the expression of biomarkers such as gene expression, TP53 gene mutations, transcription factor FOSB, circulating tumor cells (CTC), and peripheral blood inflammatory factors, which can predict pathological grading. Therefore, identifying reliable biomarkers for predicting pathological grading is essential for selecting appropriate treatment regimens. This review focuses on biomarkers related to LUAD pathological grading prediction, aiming to facilitate the development of individualized treatment plans and improve prognosis.

关 键 词：肺腺癌 生物标志物 病理分级 预后 

分 类 号：R73[医药卫生—肿瘤]